Not sure FWIW
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
June 14, 2016
ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934
CTI BioPharma Corp.
File No. 1-12465 - CF#33661
_____________________________
CTI BioPharma Corp. (formerly Cell Therapeutics, Inc.) submitted an application
under Rule 24b-2 requesting an extension of previous grants of confidential treatment for
information it excluded from the Exhibits to a Form 10-Q filed on May 2, 2013, a Form
10-Q filed on July 31, 2013 and a Form 10-Q filed on April 29, 2014.
Based on representations by CTI BioPharma Corp. that this information qualifies
as confidential commercial or financial information under the Freedom of Information
Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to
publicly disclose it. Accordingly, excluded information from the following exhibits will
not be released to the public for the time periods specified:
Exhibit to Form Filed on
Confidential Treatment
Granted
10.7 10-Q May 2, 2013 through March 27, 2021
10.1 10-Q July 31, 2013 through March 27, 2021
10.2 10-Q July 31, 2013 through March 27, 2021
10.3 10-Q April 29, 2014 through March 27, 2021
